Reuters logo
BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD
June 21, 2017 / 4:52 PM / 3 months ago

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

June 21 (Reuters) - Supernus Pharmaceuticals Inc:

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

* Shire expects to make Mydayis commercially available in United States in Q3 of 2017

* Based on agreement between Supernus, Shire, Shire will pay to Supernus single digit percentage royalty on net sales of product Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below